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ABSTRACT:	  
	  
Purpose:	  We	   aimed	   to	   determine	   the	   impact	   of	   SPECT/CT	   performed	   in	   addition	   to	   whole-­‐body	  
scintigraphy	   augmented	   with	   prone	   lateral	   views	   in	   patients	   with	   well-­‐differentiated	   thyroid	  
carcinoma.	  	  
Methods	  and	  Materials:	  This	  retrospective	  study	   included	  141	  patients	   (87	  female,	  54	  male,	  mean	  
age	  47	  years)	  with	  well-­‐differentiated	   thyroid	   carcinoma	   (105	  papillary,	  31	   follicular,	   1	  Hürthle	   cell	  
and	   4	   poorly	   differentiated)	   treated	   with	   radioiodine	   therapy	   (1000–7400	   MBq).	   Patients	   were	  
referred	   for	   either	   first	   postsurgical	   therapy	   (n=76)	   or	   further	   treatment	   (n=65).	   Two	   nuclear	  
medicine	   physicians	   interpreted	   the	   scans	   in	   consensus	   (first	   whole-­‐body	   scintigraphy	   with	   prone	  
lateral	  view,	  then	  SPECT/CT)	  reporting	  abnormal	  iodine	  uptake	  in	  the	  thyroid	  bed,	  lymph	  nodes	  and	  
distant	  metastasis.	  The	  corresponding	  ATA	  risk	  score	  was	  calculated	  for	  each	  patient	  before	  and	  after	  
SPECT/CT,	  as	  well	  as	  change	  in	  disease	  extension	  
Results:	  The	  analysis	  showed	  a	  difference	  between	  scintigraphy	  and	  SPECT/CT	  in	  n=17	  lesions	  in	  14	  
patients	  (9.9%):	  12	  were	  described	  as	  suspicious	  on	  scintigraphy	  and	  could	  be	  considered	  as	  benign	  
on	  SPECT/CT	  (3	  corresponded	  to	  local	   iodine	  uptake,	  6	  to	  lymph	  nodes	  metastases	  and	  3	  to	  distant	  
metastases).	  The	  others	  5	  corresponded	  to	  metastases	  (4	  lymph	  nodes	  and	  1	  distant)	  that	  were	  not	  
seen	  on	  whole-­‐body	  scintigraphy	  augmented	  with	  prone	  lateral	  views.	  In	  10	  of	  141	  (7.1%)	  patients,	  
we	  observed	  a	  change	  in	  ATA	  risk	  stratification,	  with	  a	  risk	  increase	  in	  4	  of	  them	  (2.8%).	  
Conclusion:	  SPECT/CT	  allowed	  detecting	  5	  focal	  lesions	  missed	  on	  planar	  scintigraphy,	  and	  to	  precise	  
benignity	   of	   12	   suspicious	   lesions	   on	   planar	   scintigraphy.	   Moreover,	   SPECT/CT	   improved	   the	   risk	  
stratification	  in	  10	  patients	  with	  a	  significant	  change	  in	  the	  patient	  management	  
Key	  	  Words:	  differentiated	  thyroid	  cancer,	  radioiodine	  scintigraphy,	  SPECT/CT,	  risk	  classification	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INTRODUCTION:	  
	  
Well	   differentiated	   thyroid	   cancer	   accounts	   for	   nearly	   1%	   of	   all	   cancer	   cases,	   with	   an	   increasing	  
incidence	   (1,2).	   Thanks	   to	   a	   right	   therapy,	   this	   type	   of	   cancer	   has	   a	   favorable	   prognosis	   and	   good	  
survival	   rates	   (3).	   The	   standard	   treatment	   includes	   surgical	   resection	   (near-­‐total	   or	   total	  
thyroidectomy)	   and	   131I	   radio-­‐ablation	   (4,5)	   to	   remove	   any	   physiological	   and	   pathologic	   remnant	  
post-­‐surgery.	  	  	  
To	  help	  to	  better	  plan	  further	  treatments	  for	  the	  patients,	  guidelines	  for	  thyroid	  cancer	  management	  
were	   published	   by	   the	   American	   Thyroid	   Association	   (ATA)	   to	   define	   risk	   stratification.	   Many	  
parameters	  are	  included,	  i.e.	  tumor	  histology,	  surgical	  resection,	  local	  or	  distant	  metastasis	  and	  post-­‐
therapy	  scan	  results	  (4).	  These	  criteria	  allow	  grouping	  patients	  in	  3	  different	  risk	  categories.	  No	  local	  
or	  distant	  metastases,	  complete	  surgical	  resection,	  no	  invasion	  of	  locoregional	  structures,	  no	  vascular	  
invasion	  are	  the	  criteria	  for	  a	  low-­‐risk	  patient.	  Patients	  are	  classified	  as	  intermediate-­‐risk	  patients	  if	  
they	   have	   aggressive	   histology	   or	   vascular	   invasion,	   microscopic	   invasion	   into	   perithyroidal	   soft	  
tissues	  at	   initial	   surgery	  or	  cervical	   lymph	  nodes	  metastases.	  High-­‐risk	  patient	  are	  characterized	  by	  
macroscopic	   tumor	   invasion,	   incomplete	   resection	  or	  distant	  metastases	   (4).	   This	   risk	   stratification	  
allows	  to	  determine	  the	  patient	  management:	  further	  treatment,	  frequency	  and	  intensity	  of	  follow-­‐
up	  (6,7).	  	  
Imaging	   is	   important	  to	  determine	  the	  risk	   for	  the	  patient.	  The	  whole-­‐body	  planar	  scintigraphy	   is	  a	  
good	   tool	   to	   detect	   iodine	   uptakes	   in	   post-­‐thyroidectomy	   patients.	   However,	   scintigraphy	   images	  
don’t	  allow	  to	  precise	  the	  anatomical	   localization	  and	  the	  nature	  of	   iodine	  uptake,	  whether	  normal	  
or	  abnormal.	  Moreover,	   it	  has	  a	   low	   resolution.	   SPECT/CT	  has	  been	  a	  useful	   tool	   to	   fill	   this	   gap	  of	  
scintigraphy:	   not	   only	   it	   permits	   to	   precise	   the	   anatomical	   localization,	   but	   also	   the	   nature	   of	  
radioactive	  foci	  (benign	  or	  malignant),	  improving	  the	  interpretation	  of	  radioiodine	  scintigraphy	  (7).	  
In	   our	   center,	   we	   perform	   additional	   prone	   lateral	   views	   to	   the	   planar	   scintigraphy,	   which	   give	   a	  
more	   detailed	   and	   precise	   stage	   than	   the	   whole-­‐body	   scintigraphy	   alone,	   but	   the	   combination	   of	  
both	  techniques	  still	  results	  in	  a	  lack	  of	  anatomical	  details.	  For	  this	  reason,	  the	  SPECT/CT	  completes	  
the	  imaging.	  
The	   objective	   of	   this	   study	   is	   to	   determine	   retrospectively	   the	   impact	   of	   SPECT/CT	   performed	   in	  
addition	   to	   whole-­‐body	   scintigraphy	   with	   prone	   lateral	   views	   in	   patients	   with	   well-­‐differentiated	  
thyroid	  carcinoma	  in	  our	  institution,	  to	  see	  how	  often	  the	  ATA	  risk	  stratification	  changes.	  	  
	  
MATERIALS	  AND	  METHODS:	  
	  
This	   retrospective	   study	   included	   141	   patients	   (87	   female	   and	   54	   male)	   with	   well-­‐differentiated	  
thyroid	  carcinoma	  treated	  with	  131I	  between	  November	  2008	  (first	  date	  when	  the	  SPECT/CT	  was	  used	  
for	  thyroid	  images	  regarding	  this	  type	  of	  cancer	  at	  our	  Nuclear	  Medicine	  Department)	  and	  June	  2013.	  
The	  mean	  age	  of	  the	  patients	  was	  47	  years	  ±	  14	  and	  the	  range	  was	  from	  17	  to	  82	  years.	  The	  subjects	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were	  referred	  to	  our	  center	  either	  for	  first	  postsurgical	  treatment	  (n=76)	  or	  for	  recurrent	  disease,	  so	  
further	   treatment	   (n=65).	   Every	   patient	   needed	   to	   have	  well-­‐differentiated	   thyroid	   cancer:	   105	   of	  
them	  had	  papillary	  type,	  31	  of	  them	  had	  follicular	  one,	  4	  of	  them	  a	  poor	  differentiated	  one,	  and	  only	  
one	   had	   Hürthle	   cell	   cancer.	   They	   all	   underwent	   radioiodine	   therapy	   after	   near-­‐total	   or	   total	  
thyroidectomy.	  	  
After	  having	  received	  a	  mean	  activity	  of	  3403	  MBq	  ±	  1034	  and	  a	  range	  from	  1000	  to	  7400	  MBq,	  post	  
therapy	   imaging	  was	   performed	   between	   2	   and	   8	   days	   after	   131I	   capsule	   administration.	   For	   each	  
patient	  were	  performed	  anterior	  and	  posterior	  whole	  body	  planar	   scintigraphy,	  at	   least	  one	  prone	  
lateral	  static	  view	  and	  SPECT/CT.	  Every	  scan	  included	  head	  and	  neck	  region	  and	  at	  least	  the	  thorax.	  
All	  patients	  underwent	  scintigraphy	  imaging	  and	  SPECT/CT	  on	  the	  same	  day.	  Initially,	  the	  scintigraphy	  
with	  prone	   lateral	  views	  was	  performed	  by	  using	  a	  dual	  head	  gamma-­‐camera	   (Biad,	  Trionix;	   Infinia	  
Hawkeye	   IV,	   GE	   Healthcare;	   Discovery	   NM670,	   GE	   Healthcare).	   Thereafter	   the	   SPECT/CT	   was	  
performed	  (Infinia	  Hawkeye	  IV,	  GE	  Healthcare;	  Discovery	  NM670,	  GE	  Healthcare).	  	  
To	  compare	  scintigraphy	  and	  SPECT/CT	  findings	  at	  our	  institution,	  two	  experienced	  nuclear	  medicine	  
physicians	   interpreted	   the	  different	   scans	   for	   each	  patient.	   They	   could	  have	   information	   regarding	  
the	  type	  of	  cancer,	  the	  thyroglobulin	  level	  or	  prior	  treatment	  results.	  Their	  task	  was	  to	  evaluate	  the	  
iodine	  uptake	  and	  categorize	  it,	  by	  reporting	  every	  abnormal	  uptake.	  For	  each	  scan	  review,	  they	  had	  
to	  agree	  with	  each	  other.	  If	  discordances	  between	  the	  two	  physicians	  occurred,	  a	  discussion	  had	  to	  
be	   made	   to	   reach	   a	   consensus.	   At	   the	   beginning	   they	   interpreted	   the	   scans	   separately,	   but	   we	  
decided	   that	   a	   discussion	   together	   and	   immediate	   was	  more	   productive,	   so	   we	   changed	  method	  
during	  the	  review	  process.	  They	  started	  at	  first	  with	  the	  scintigraphy	   images	  (both	  whole	  body	  and	  
prone	   lateral	   static	  views	   together).	   If	   the	  uptake	  was	   localized	  on	   the	  medial	  portion	  of	   the	  neck,	  
they	  categorized	  it	  as	  positive	  for	  tumoral	  or	  physiological	  remnant.	  If	  it	  was	  located	  laterally	  in	  the	  
neck	  or	  in	  the	  mediastinal	  region	  and	  obviously	  not	  in	  the	  thyroid	  bed,	  it	  was	  considered	  as	  positive	  
for	   lymph	   nodes	   metastases.	   Radioactive	   foci	   located	   outside	   the	   neck	   or	   the	  mediastinum	   were	  
categorized	  as	  positive	  for	  distant	  metastasis,	  when	  they	  clearly	  were	  not	  physiologic	  accumulation	  
(nose,	   salivary	   glands,	   stomach,	   intestines,	   etc.)	   Once	   the	   iodine	   uptake	   was	   categorized	   for	   the	  
scintigraphy,	  they	  could	  analyze	  the	  SPECT/CT	  scans.	  Likely	  for	  the	  first	  part,	  SPECT/CT	  findings	  were	  
described	   to	   categorize	   the	   iodine	   uptake	   as	   local	   residue,	   lymph	   nodes	   metastasis	   or	   distant	  
metastasis.	   It’s	   important	   to	   underline	   that	   the	   two	   nuclear	   medicine	   physicians	   could	   only	  
characterize	  the	  findings	  as	  benign	  or	  malignant.	  Even	  if	  a	  lesion	  was	  equivocal	  for	  them,	  they	  always	  
had	  to	  categorize	  the	  uptake	  as	  local	  residue,	  lymph	  node	  or	  distant	  metastasis.	  
Then	   the	  ATA	  risk	   score	  was	  calculated	   for	  each	  patient	   to	  know	  how	  often	  SPECT/CT	  changes	   the	  
initial	   risk	   stratification.	   Presence	   of	   only	   tumoral	   or	   physiological	   residue	   determines	   a	   low	   risk.	  
Iodine	   uptake	   in	   lymph	   nodes	   means	   intermediate	   risk.	   Patients	   with	   distant	   metastasis	   are	  
categorized	  as	  high-­‐risk	  patients.	  So	  if	  new	  distant	  metastases	  were	  identified	  on	  the	  SPECT/CT,	  the	  
risk	   would	   elevate	   the	   risk	   from	   low	   or	   intermediate	   to	   high.	   Iodine	   uptake	   in	   neck	   lymph	   nodes	  
would	  change	  a	  low	  risk	  patient	  to	  an	  intermediate	  one	  and	  vice	  versa.	  According	  to	  the	  guidelines	  by	  
Cooper	  et	  al.	  (4),	  the	  risk	  attribution	  considered	  also	  the	  tumor	  histology,	   invasion	  at	   initial	  surgery	  
and	   the	   resection.	   Once	   we	   have	   one	   score	   for	   the	   scintigraphy	   and	   one	   for	   the	   SPECT/CT,	   we	  
compare	   them	   and	   see	   if	   there	   is	   an	   improvement	   of	   the	   risk	   or	   not,	   considering	   planar	   and	  
SPECT/CT	  findings.	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A	  statistical	  analysis	  is	  then	  done	  to	  determine	  the	  different	  percentages	  and	  to	  see	  the	  contribution	  
of	  the	  SPECT/CT	  on	  the	  risk	  stratification.	  
	  	  
	   All	   First	  treatment	   Further	  treatment	  
	   	   	   	  
Patients	   141	   76	  (54)	   65	  (46)	  
	   	   	   	  
Sex	   	   	   	  
	  	  Male	   54	  (38.3)	   25	  (32.9)	   29	  (44.6)	  
	  	  Female	   87	  (61.7)	   51	  (67.9)	   36	  (55.4)	  
	   	   	   	  
Age	  (year)	   	   	   	  
	  	  Mean	  ±	  SD	   47	  ±	  16	   47	  ±	  14	   48	  ±	  18	  
	  	  Range	  	   17	  -­‐	  82	   17	  -­‐	  78	   17	  -­‐	  82	  
	   	   	   	  
Histology	   	   	   	  
	  	  Papillary	   105	  (74.5)	   57	  (75)	   48	  (73.8)	  
	  	  Follicular	   31	  (22)	   18	  (23.7)	   13	  (20)	  
	  	  Poorly	  
differentiate
d	  
4	  (2.8)	   1	  (1.3)	   3	  (4.6)	  
	  	  Hürthle	  cell	   1	  (0.8)	   0	  (0)	   1	  (1.5)	  
	   	   	   	  
131I	  Activity	  
(MBq)	  
	   	   	  
	  	  Mean	  ±	  SD	   3403	  ±	  1034	   2933	  ±	  919	   3952	  ±	  883	  
	  	  Range	   1000	  -­‐	  7400	   1000	  -­‐	  3859	   2000	  -­‐	  7400	  
	  
Data	  in	  parentheses	  are	  percentages.	  
	  	  	  	  	  	  	  	  Table	  1:	  Patient	  demographics	  
	  
RESULTS	  
The	  analysis	  showed	  a	  difference	  between	  scintigraphy	  and	  SPECT/CT	  in	  n=17	  lesions	  in	  14	  patients	  
(9.9%):	  n=8	  in	  6	  patients	  referred	  for	  a	  first	  treatment	  and	  n=9	  in	  8	  patients	  with	  further	  treatment.	  
In	  n=12	  lesions	  in	  10	  patients	  (7.1%)	  were	  suspicious	  on	  scintigraphy,	  but	  they	  could	  be	  considered	  as	  
benign	  on	  SPECT/CT	  (n=3	  corresponded	  to	  local	   iodine	  uptake,	  n=6	  to	  lymph	  nodes	  metastases	  and	  
n=3	   to	   distant	   metastases).	   The	   others	   n=5	   found	   in	   5	   patients	   (3.5%)	   lesions	   corresponded	   to	  
metastasis	   that	  weren’t	  seen	  on	  whole-­‐body	  scintigraphy	  augmented	  with	  prone	   lateral	  views:	  n=4	  
lymph	  nodes	  metastases	  and	  n=1	  distant	  metastasis.	  
Thyroid	  bed	  
During	   the	   scintigraphy	   scans	   review,	   iodine	   uptakes	   in	   the	   thyroid	   bed	   (tumoral	   or	   physiological	  
residue)	  were	  found	  in	  131	  patients,	  which	  means	  in	  92.2%	  of	  the	  patients.	  	  On	  the	  SPECT/CT	  scans,	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128	  patients	  (90.8%)	  had	  positive	  uptake	  in	  this	  region.	  In	  3	  patients	  (2.1%)	  uptake	  was	  present	  in	  the	  
scintigraphy	  and	  not	  observed	  on	  the	  SPECT/CT	  scan.	   In	   the	   first	   treatment	  cohort,	   the	   findings	  on	  
scintigraphy	   correlated	   with	   the	   findings	   on	   SPECT/CT.	   In	   patients	   with	   further	   treatment,	  
disagreement	  was	  observed	  in	  3	  of	  65	  patients.	  
Lymph	  nodes	  metastases	  
Twenty-­‐two	  patients	  (15.6%)	  were	  described	  with	  lymph	  nodes	  metastases	  on	  the	  scintigraphy	  (n=11	  
for	  each	  first	  and	  further	  treatment).	  On	  the	  contrary,	  n=20	  lymph	  nodes	  metastases	  (n=8	  for	  first	  vs.	  
n=12	   for	   further	   treatment)	  were	   found	  on	  SPECT/CT	   (14.2%).	  A	   certain	  number	  of	  patients	  had	  a	  
change	   in	   the	   localization	   of	   the	   pathological	   lymph	   nodes.	   The	   analysis	   showed	   a	   difference	  
between	  scintigraphy	  and	  SPECT/CT	   in	  n=10	   lymph	  nodes	   lesions	   in	  10	  patients	   (7.1%):	  n=6	   (4.3%)	  
were	  described	  as	   suspicious	  on	  scintigraphy	  and	  could	  be	  considered	  as	  benign	  on	  SPECT/CT.	  The	  
others	  4	   (2.8%)	  corresponded	  to	   lymph	  nodes	  metastasis	   found	  on	  SPECT/CT	  that	  weren’t	  seen	  on	  
whole-­‐body	  scintigraphy	  with	  prone	  lateral	  views.	  In	  the	  patients	  who	  underwent	  a	  first	  therapy,	  n=4	  
lymph	   nodes	   metastases	   have	   been	   described	   on	   the	   scintigraphy	   but	   not	   on	   SPECT/CT	   and	   n=1	  
patient	  had	  a	  lymph	  node	  metastasis	  on	  SPECT/CT	  that	  wasn’t	  seen	  on	  scintigraphy.	  On	  the	  contrary	  
regarding	  the	  patients	  with	  a	  further	  treatment,	  n=2	  lesions	  were	  found	  only	  on	  scintigraphy	  and	  n=3	  
lymph	  nodes	  metastases	  were	  discovered	  on	  SPECT/CT	  and	  not	  seen	  on	  the	  scintigraphy.	  
Distant	  metastases	  
A	  total	  of	  6	  patients	  (4.3%)	  had	  distant	  metastases	  on	  the	  whole	  body	  scintigraphy	  with	  prone	  lateral	  
views:	  n=2	  of	  them	  during	  the	  first	  radiotherapy	  and	  n=4	  during	  a	  further	  treatment.	  	  On	  SPECT/CT,	  
n=4	   lesions	   (2.8%)	   were	   described	   as	   positive	   for	   distant	   metastases:	   n=1	   in	   patients	   with	   first	  
therapy,	  n=3	  in	  those	  with	  further	  treatment.	  Changes	  between	  scintigraphy	  and	  SPECT/CT	  occurred	  
Figure	   1.	   A	   34	   year-­‐old	   man	   with	  
papillary	   thyroid	   cancer,	   second	  
radioiodine	   therapy,	   3	   days	   after	  
administration	  	  of	  3700	  Mbq	  131I.	  On	  the	  
whole-­‐body	  scintigraphy	  	  (on	  the	  left)	  an	  
asymetrical	   uptake	   can	   be	   seen	   on	   the	  
right	   side	   of	   the	   neck.	  With	   the	   help	   of	  
the	   lateral	   view,	   this	   uptake	   was	  
considered	   as	   benign	   because	   of	   its	  
location	   (it	   can	   be	   a	   submandibular	  
gland).	   For	   this	   reason,	   the	   patient	  was	  
classified	  with	   a	   low	  ATA	   risk	   score.	   On	  
the	  SPECT/CT	  (on	  the	  right)	  this	  uptake	  is	  
located	   in	   a	   neck	   lymph	   node	   (see	   the	  
arrow).	   This	   proves	   the	   malignant	  
characteristic	   of	   the	   uptake,	   so	   this	  
patient	   went	   from	   a	   low	   to	   an	  
intermediate	  risk.	  
	  
	   9	  
in	  n=4	  lesions	  in	  4	  patients	  (2.8%).	  3	  of	  them	  (2.1%)	  were	  described	  M1	  on	  scintigraphy,	  but	  M0	  on	  
SPECT/CT	  (n=2	  first	  vs.	  n=1	  further	  treatment).	  SPECT/CT	  helped	  discovering	  a	  distant	  metastasis	  not	  





Figure	  3.	  Difference	  in	  patient	  positive	  findings	  between	  SPECT/CT	  and	  scintigraphy	  
ATA	  risk	  
On	  scintigraphy,	  n=97	  patients	  (68,8%)	  were	  classified	  as	  low	  risk	  patients,	  n=34	  patients	  (24.1%)	  as	  
intermediate	  risk	  one	  and	  n=10	  (7.1%)	  patients	  as	  high	  risk	  ones.	  On	  the	  contrary,	  on	  the	  SPECT/CT	  





Local	  	   Lymph	  Nodes	   Distant	  metastases	  
Scintigraphy	  SPECT/CT	  
Figure	   2.	   A	   65-­‐year-­‐old	   woman	  
with	   papillary	   thyroid	   cancer,	  
second	  radioiodine	  therapy,	  3	  days	  
after	  administration	   	  of	  3700	  Mbq	  
131I.	   The	   whole-­‐body	   scintigraphy	  	  
(on	   the	   left)	   shows	   an	   isolated	  
iodine	   uptake	   (see	   the	   arrow),	  
which	   can	   suggest	   a	   bone	  
metastasis.	   So	   the	   patient	   was	  
classified	   with	   a	   high	   ATA	   risk	  
score.	  The	  SPECT/CT	  (on	  the	  right)	  
shows	  its	  hepatic	  location,	  which	  is	  
not	  a	  usual	  metastasis	  location	  for	  
this	   cancer.	   In	   fact,	   it	   corresponds	  
to	   a	   hemangioma.	   This	   patient	  
went	  from	  a	  high	  to	  a	  low	  risk	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high-­‐risk	  ones	  n=8	  (5.7%).	  A	  change	  in	  ATA	  risk	  stratification	  between	  whole	  body	  scintigraphy	  with	  
prone	   lateral	  views	  and	  SPECT/CT	   is	  observed	   in	  10	  patients	  (7.1%).	   In	  n=4	  patients	  (2.8%)	  the	  ATA	  
risk	   increased:	   n=3	   of	   them	   (2.1%)	   from	   a	   low	   risk	   to	   an	   intermediate	   one	   and	   n=1	   post-­‐surgical	  
patient	  (0.7%)	  from	  an	  intermediate	  risk	  to	  a	  high	  one.	  On	  the	  contrary,	  n=6	  patients	  (4.3%)	  showed	  
a	  decreased	  ATA	  risk	  score	  after	  SPECT/CT:	  n=4	  (2.8%)	  from	  a	  high	  to	  a	  low	  risk,	  n=2	  (1.4%)	  from	  an	  
intermediate	  to	  a	  low	  risk.	  Others	  details	  are	  showed	  on	  table	  2.	  	  
	  
Figure	  4.	  Difference	  in	  patient	  ATA	  risk	  score	  between	  SPECT/CT	  and	  scintigraphy	  
	  
Patient	   Age	   Sex	   Therapy	   Histology	   ATA	  Risk	  for	  Scintigraphy	  
ATA	  Risk	  for	  
SPECT	   Diagnostic	  
1	   32	   F	   2nd	   papillary	   low	   	  	  intermediate	   	  
2	   34	   M	   2nd	   papillary	   low	   	  	  intermediate	   	  
3	   42	   F	   1st	   papillary	   low	   intermediate	   	  
4	   52	   F	   1st	   follicular	  (oncocytic	  type)	   intermediate	   high	  
Poor	  iodophile	  
pulmonary	  mass	  
5	   51	   M	   1st	   papillary	   intermediate	   low	   	  
6	   48	   M	   2nd	   papillary	   intermediate	   low	   	  
7	   58	   F	   2nd	   papillary	  (follicular	  type)	   intermediate	   low	   	  





9	   30	   F	   1st	   follicular	   high	   low	   contamination	  
10	   65	   F	   2nd	   papillary	   high	   low	   Liver	  hemangioma	  
	  








Low	   Intermediate	   High	  
Scintigraphy	  SPECT/CT	  








131Iodine	  scintigraphy	  is	  an	  important	  initial	  and	  primary	  tool	  for	  the	  detection	  of	  this	  disease	  in	  post	  
surgery	  patients	  with	  well-­‐differentiated	  thyroid	  carcinoma.	  With	  the	  introduction	  of	  new	  technique,	  
it	   was	   proved	   that	   SPECT/CT	   provides	   additional	   information	   to	   the	   scintigraphy	   (6–18),	   with	   a	  
benefit	  on	  the	  patient	  management,	  linked	  to	  the	  more	  accurate	  localization	  and	  characterization	  of	  
nature	  of	  the	  iodine	  uptake.	  	  
In	   our	   study,	   there	   is	   a	   difference	   between	  whole-­‐body	   scintigraphy	  with	   prone	   lateral	   views	   and	  
SPECT/CT	  in	  17	   lesions	  (12.1%).	   It’s	  a	   lower	  rate	  of	  changed	  findings	  from	  scintigraphy	  to	  SPECT/CT	  
compared	  with	  others	  studies,	  which	  vary	  from	  20%	  (6)	  to	  74%	  (3).	  The	  results	  diverge	  especially	  in	  
relation	  to	  different	  methodology.	  
One	   of	   the	   reasons	   of	   the	   difference	   in	   the	   results	   between	   the	   studies	   can	   be	   the	   timing	   of	   the	  
scans:	  SPECT/CT	  before	  radioiodine	  therapy	  (9,12,14),	  post-­‐therapy	  (5,9,10,	  14,18,19)	  or	  a	  mixture	  of	  
both	   (13).	   More	   radioiodine	   foci	   can	   be	   detected	   in	   the	   post-­‐therapy	   scans,	   because	   target-­‐to-­‐
background	   ratio	   is	   more	   important,	   in	   reason	   of	   the	   higher	   radioiodine	   activity	   and	   the	   longer	  
interval	  between	  activity	  administration	  and	  imaging	  (20–23).	  
In	  this	  study	  the	  SPECT/CT	  was	  obtained	   in	  all	  patients	   independently	  on	  the	  findings	   in	  the	  planar	  
imaging,	  so	  every	  subject	  had	  a	  SPECT/CT	  scan	  that	  included	  head	  and	  neck	  region	  and	  at	   least	  the	  
thorax.	   In	  the	  contrary,	   in	  some	  others	  articles	  (9,11,13,3,19),	   the	  SPECT/CT	  was	  performed	  only	   in	  
	  
ATA	  LOW-­‐RISK	   ATA	  INTERMEDIATE-­‐RISK	   ATA	  HIGH-­‐RISK	  
n=3	   	  	  	  	  n=1	  
n=3	  
	  	  	  n=3	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the	  contest	  of	  equivocal	  scintigraphy.	  Not	  only	  it’s	  a	  source	  of	  selection	  bias,	  but	  it	  can	  also	  result	  in	  
missing	   some	   lesions	   that	   were	   hidden	   in	   clear	   scintigraphy	  with	   no	   uptake.	   In	   fact,	   some	   of	   our	  
patients	  had	  a	  planar	  scintigraphy	  that	  wasn’t	  equivocal	  for	  malignant	  lesions	  that	  were	  then	  seen	  on	  
the	  SPECT/CT.	  	  
Another	  reason	  of	  the	  difference	  with	  others	  results	  is	  the	  consideration	  of	  the	  prone	  lateral	  views	  in	  
our	   institution.	  The	  anterior	  and	  posterior	  projections	  of	   the	  whole-­‐body	  scintigraphy	  don’t	  always	  
allow	  clearly	   identifying	   the	   thyroid	  bed	  residues	  or	   the	   localization	  of	   lymph	  nodes	  metastases.	   In	  
our	   institution,	   we	   also	   performed	   the	   prone	   lateral	   views,	   with	   the	   conviction	   that	   they	   give	  
additional	   information	   thanks	   to	   a	   projection	   of	   the	   uptakes	   in	   a	   sagittal	   plane	   view.	   In	   many	  
patients,	  these	  lateral	  views	  allowed	  to	  make	  the	  difference	  between	  a	  more	  probable	  lymph	  node	  
uptake	  and	  a	  physiological	  remnant.	  However,	  even	  if	  the	  lateral	  views	  helped	  to	  better	  identify	  the	  
status	   and	   they	  were	   carefully	   analyzed,	   the	  uptakes	  were	  often	   equivocal	   and	   the	   anatomic	   field	  
was	  not	  defined.	  In	  fact,	  it	  wasn’t	  always	  clear	  to	  distinguish	  a	  physiological	  from	  pathologic	  uptake	  
on	   scintigraphy	  A	   confirmation	  with	   the	   SPECT/CT	  was	  necessary	   to	  better	   characterize	   this	   lesion	  
related	  to	  better	  anatomic	  precision	  and	  the	  higher	  resolution.	  Moreover,	  It	  can	  confirm	  the	  benign	  
nature	  of	  lesions	  seen	  as	  pathologic	  to	  the	  whole	  body	  scintigraphy.	  	  
In	   our	   study,	   12	   lesions	   in	   10	   patients	   (7.1%)	   were	   described	   as	   suspicious	   on	   the	   whole	   body	  
scintigraphy	   with	   the	   prone	   lateral	   views	   and	   could	   be	   considered	   as	   benign	   on	   SPECT/CT:	   3	  
corresponded	  to	  local	  iodine	  uptakes,	  6	  to	  lymph	  nodes	  metastases	  and	  3	  to	  distant	  metastases.	  On	  
the	  opposite	  5	   lesions	   in	  5	  patients	   (3.5%)	  corresponded	  to	  pathological	  uptakes	  that	  weren’t	  seen	  
on	  the	  scintigraphy:	  4	  to	  lymph	  nodes	  metastases	  and	  1	  to	  distant	  metastasis.	  The	  SPECT/CT	  changed	  
the	  nodal	  status	  in	  10	  lymph	  nodes	  lesions	  (7.1%)	  and	  distant	  metastasis	  status	  in	  4	  lesions	  (2.8%)	  in	  
our	   study.	   That	   can	   be	   explained	   for	   many	   reasons.	   SPECT/CT	   gave	   a	   more	   precise	   anatomic	  
localization,	   which	   allowed	   a	   more	   correct	   image	   interpretation.	   In	   fact,	   it	   distinguished	   more	  
efficiently	   the	  malignant	   lesions	   from	  sites	  of	  physiologic	   (salivary	  glands,	  esophagus,	   thyreoglossal	  
duct)	  or	  remnant	  uptake,	  which	  can	  interfere	  with	  the	  proper	  reading	  of	  the	  scintigraphy	  images,	  not	  
always	  conclusive.	  Despite	  the	  more	  accurate	  diagnosis	  and	  stage	  with	  the	  addition	  of	  SPECT/CT,	  the	  
results	   in	  our	   study	  have	  a	   lower	   rate	   compared	  with	  other	  article.	   Schmidt	  et	  al.	   (10)	   studied	   the	  
incremental	   value	   of	   SPECT/CT	   on	   the	   nodal	   stage:	   the	   N	   status	   was	   changed	   in	   20	   (35%)	   of	   57	  
patients.	  Similar	  lymph	  nodes	  results	  (36.4%)	  are	  found	  by	  Kohlfuerst	  et	  al.	  (11),	  which	  also	  reported	  
36.4%	   of	   changes	   in	   the	   distant	  metastasis	   status.	   Grewal	   et	   al.	   (6)	   noted	   an	   alteration	   of	   lymph	  
nodes	  status	  in	  15%	  of	  the	  subjects.	  	  
In	  well-­‐differentiated	   thyroid	   cancers,	   risk	   stratification	   is	  used	   to	  predict	   the	  probability	   for	  death	  
from	  this	  disease,	  for	  local	  recurrence	  and	  for	  treatment	  failure	  (6,24).	  The	  ATA	  risk	  stratification	  in	  
our	  study	  changed	  in	  10	  of	  141	  patients	  (7.1%).	  Grewal	  et	  al.	  (6)	  also	  looked	  for	  a	  difference	  of	  the	  
risk	   of	   recurrence	   between	   scintigraphy	   and	   SPECT/CT.	   An	   altered	   risk	   of	   recurrence	   in	   7	   of	   109	  
patients	  (6.4%)	  was	  reported.	  In	  contrast	  with	  our	  study,	  all	  patients	  had	  intermediate	  or	  high	  risks.	  If	  
we	  consider	  only	  these	  types	  of	  patients,	  the	  ATA	  risk	  changes	  in	  7	  patients	  (5%)	  in	  our	  cohort.	  Since	  
our	  protocols	  are	  similar,	  the	  slight	  difference	  can	  be	  attributed	  to	  the	  prone	  lateral	  views	  added	  to	  
the	  whole-­‐body	  scintigraphy,	  which	  weren’t	  performed	  in	  their	  institution.	  It’s	  important	  to	  note	  that	  
the	  presence	  of	  abnormal	  131I	  uptake	  on	  the	  first	  post	  ablation	  scan	  is	  just	  one	  parameter	  to	  calculate	  
the	   risk:	   for	  example	  one	  patient	  had	  a	   suspicious	   lymph	  node	  metastasis	  on	   the	  scintigraphy	   that	  
wasn’t	  seen	  on	  the	  SPECT/CT	  (intermediate	  to	  low	  risk	  patient),	  but	  because	  of	  the	  invasion	  into	  the	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perithyroidal	   soft	   tissues	   at	   initial	   surgery,	   the	   patient	   continues	   to	   have	   an	   intermediate	   risk	   of	  
recurrence.	  That	   leads	  to	  a	   lower	  percentage,	  even	   if	   there	  was	  a	  radiological	  change	  that	  affected	  
the	   risk.	   Schmidt	   et	   al.	   also	   showed	   an	   alteration	   of	   the	   risk,	   and	   so	   the	   follow-­‐up,	   in	   25%	   of	   the	  
patients	  (10),	  	  which	  is	  more	  elevated	  than	  our	  rate,	  probably	  for	  the	  same	  reasons.	  
Sometimes	  an	  iodine	  uptake	  was	  classified	  differently	  between	  scintigraphy	  and	  SPECT/CT	  without	  a	  
change	  in	  the	  ATA	  risk:	   it	  happened	  for	  example	  if	  distant	  metastases	  were	  already	  present	  in	  both	  
technics,	  and	  a	  lymph	  node	  metastasis	  was	  reclassified	  as	  an	  uptake	  to	  thyroid	  bed.	  In	  this	  case	  the	  
patient	  still	  has	  a	  high	  risk,	  but	  SPECT/CT	  helped	  to	  precise	  the	  diagnostic.	  In	  many	  cases,	  SPECT/CT	  
was	  useful	  to	  find	  others	  lesions	  without	  changing	  the	  stage:	  for	  example	  if	  another	  lymph	  node	  in	  a	  
different	   localization	   was	   found	   in	   addition	   to	   the	   one	   already	   seen	   on	   the	   scintigraphy.	   The	   risk	  
remained	   intermediate,	   even	   if	   SPECT/CT	   could	   help	   to	   choose	   a	   different	   treatment	   approach.	  
Others	   pathological	   lesions,	   not	   related	   to	   the	   thyroid	   cancer,	   were	   occasionally	   found	   (liver	  
hemangioma,	  sinusitis,	  etc.)	  
Because	  of	   the	   impossibility	   for	   the	  nuclear	  medicine	  physician	  to	  consider	  equivocal	  an	  uptake	  on	  
the	  whole	  body	  scintigraphy	  with	  the	  lateral	  views;	  they	  classified	  some	  lesions	  based	  of	  probability	  
according	   to	   other	   information	   given	   (histology,	   thyroglobulin	   level,	   etc.).	   Thyroglobulin	   level	  may	  
help	  to	  exclude	  tumor	  if	  a	  suspect	  uptake	  was	  correlated	  to	  a	  low	  level.	  The	  SPECT/CT	  increased	  such	  
cases	  the	  diagnostic	  certitude	  and	  it	  was	  determinant	  in	  patients	  with	  unclear	  scintigraphy.	  	  
This	  study	  had	  some	  limitations.	  First	  of	  all	   it	  did	  not	  allow	  to	  consider	  as	  equivocal	  a	   lesion	  during	  
the	  scan	  review.	  It	  results	  in	  an	  absence	  of	  rate	  of	  the	  lesion,	  in	  which	  SPECT/CT	  helped	  to	  describe	  
better	  the	  nature	  of	  the	   iodine	  uptake.	  During	  the	  scan	   interpretation,	   it	  often	  occurred	  that	  some	  
lesions	  were	  equivocal	  by	  the	  two	  nuclear	  medicine	  physicians,	  but	  they	  had	  to	  give	  an	  answer,	  so	  
they	   gave	   the	   most	   probable.	   In	   those	   cases,	   the	   SPECT/CT	   was	   useful	   to	   categorize	   the	   iodine	  
uptake.	  
To	  see	  a	  better	  help	  from	  the	  prone	  lateral	  views,	  it	  should	  have	  been	  better	  to	  analyze	  the	  anterior	  
and	  posterior	  projections	  separately	  from	  the	  prone	  lateral	  views,	  to	  see	  how	  often	  the	  situations	  on	  
the	  lateral	  views	  allowed	  to	  clarify	  some	  status.	  Moreover,	  some	  of	  the	  patients	  had	  only	  one	  lateral	  
view.	  We	  decided	  to	  include	  these	  patients	  because	  they	  gave	  us	  another	  point	  of	  view	  compared	  to	  
whole	  body	  scintigraphy.	  However,	  having	  two	  prone	  lateral	  views	  give	  a	  better	  condition	  to	  describe	  
and	  make	  the	  difference	  between	  local	  uptake	  and	  lymph	  nodes	  metastases.	  
Most	   of	   the	   high-­‐risk	   patients	   are	   not	   included,	   because	   the	  whole	   body	   scintigraphy	  was	   already	  
clear	   and	   so	   a	   SPECT/CT	  was	   directly	   done	  without	   the	   lateral	   prone	   views.	   That	   could	   result	   in	   a	  
selection	  bias.	  	  
It’s	  important	  to	  precise	  also	  that	  there	  is	  a	  learning	  curve	  of	  the	  scans	  reader:	  the	  physicians	  could	  
improve	  the	  analysis	  during	  the	  study.	  
During	  the	  time	  of	  the	  study,	  another	  SPECT/CT	  machine	  (Discovery	  NM	  670)	  arrived	  and	  so	  some	  of	  
the	  last	  subjects	  had	  this	  new	  machine	  and	  others	  had	  the	  old	  one.	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CONCLUSION:	  
	  
This	   study	  confirmed	   the	  utility	  of	  SPECT/CT:	   in	   relation	   to	   the	  anatomical	   landmarks	  and	   the	  high	  
resolution,	  it	  improves	  the	  findings	  of	  131I	  scintigraphy.	  It	  allows	  to	  confirm	  the	  diagnostic,	  reclassify	  
the	  disease	  in	  some	  cases	  and	  provide	  a	  more	  correct	  prognosis.	  The	  additional	  prone	  lateral	  views	  
permitted	  to	  clarify	  the	  situation	  by	  making	  a	  first	  differentiation	  between	  thyroid	  bed	  remnant	  and	  
lymph	   nodes	  metastases,	   resulting	   in	   a	   reduced	   rate	   of	   changed	   finding	   between	   the	  whole-­‐body	  
scintigraphy	  and	  the	  SPECT/CT	  compared	  with	  previews	  studies.	  	  
SPECT/CT	  allowed	  detecting	  5	  focal	  lesions	  in	  5	  patients	  missed	  on	  planar	  scintigraphy,	  and	  to	  precise	  
benignity	   of	   12	   suspicious	   lesions	   in	   10	   patients	   on	   planar	   scintigraphy.	   Moreover,	   SPECT/CT	  
improved	   the	   risk	   stratification	   in	   7%	   of	   the	   patients	   with	   a	   significant	   change	   in	   the	   patient	  
management,	  leading	  to	  an	  appropriated	  therapeutic	  strategy	  (alteration	  of	  the	  dose	  administration	  
or	  further	  surgical	  neck	  dissection)	  and	  avoiding	  unnecessary	  treatment.	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